This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New Strong Buy Stocks for September 13th
by Zacks Equity Research
ARCT, MHO, FMBH, PAM and ANGO have been added to the Zacks Rank #1 (Strong Buy) List on September 13, 2024.
New Strong Buy Stocks for September 9th
by Zacks Equity Research
DEC, AFRM, CRNC, ANGO and GIII have been added to the Zacks Rank #1 (Strong Buy) List on September 9, 2024.
AngioDynamics Stock Falls Despite CE Mark for Auryon System
by Zacks Equity Research
ANGO's Auryon Atherectomy System earns CE Mark, which expands its European market reach and enhances PAD treatment with advanced laser technology.
AngioDynamics (ANGO) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
AngioDynamics (ANGO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AngioDynamics (ANGO) Down 3.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Accuray's (ARAY) Radixact for Cancer Treatment Debuts in US
by Zacks Equity Research
Accuray's (ARAY) Radixact System with VitalHold technology is set to enhance precision and comfort in radiation therapy.
Does AngioDynamics (ANGO) Have the Potential to Rally 77.03% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for AngioDynamics (ANGO) points to a 77% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Should You Buy AngioDynamics (ANGO) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Boston Scientific (BSX) Rides on Global Growth, Buyouts
by Zacks Equity Research
Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.
Wall Street Analysts Predict a 74.25% Upside in AngioDynamics (ANGO): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 74.3% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
New Strong Buy Stocks for July 29th
by Zacks Equity Research
KRO, FUNC, PRG, ANGO and HGTY have been added to the Zacks Rank #1 (Strong Buy) List on July 29, 2024.
AngioDynamics (ANGO) Q4 Earnings Top Estimates, Gross Margin Down
by Zacks Equity Research
AngioDynamics (ANGO) registers overall strong top-line results on a pro-forma basis in fourth-quarter fiscal 2024, driven by strength in the Med Tech business.
AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 70% and 0.18%, respectively, for the quarter ended May 2024. Do the numbers hold clues to what lies ahead for the stock?
AngioDynamics' (ANGO) AlphaVac System Gets CE Mark Approval
by Zacks Equity Research
AngioDynamics (ANGO) announces the European CE Mark approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.
AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment
by Zacks Equity Research
AngioDynamics (ANGO) announces the FDA's approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
AngioDynamics (ANGO) Settles Patent Litigations With BD
by Zacks Equity Research
AngioDynamics (ANGO) announces its settlement agreement with BD's affiliate, C.R. Bard, to resolve a 10-year dispute over outstanding patent litigation.
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AngioDynamics (ANGO) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
In the most recent trading session, AngioDynamics (ANGO) closed at $5.37, indicating a -0.74% shift from the previous trading day.
Why AngioDynamics (ANGO) Dipped More Than Broader Market Today
by Zacks Equity Research
In the most recent trading session, AngioDynamics (ANGO) closed at $5.67, indicating a -1.39% shift from the previous trading day.
AngioDynamics (ANGO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
AngioDynamics (ANGO) closed the most recent trading day at $5.50, moving +0.18% from the previous trading session.
Here's Why AngioDynamics (ANGO) Gained But Lagged the Market Today
by Zacks Equity Research
In the most recent trading session, AngioDynamics (ANGO) closed at $5.99, indicating a +1.7% shift from the previous trading day.
AngioDynamics (ANGO) Divests Its PICC & Midline Businesses
by Zacks Equity Research
AngioDynamics (ANGO) finalizes its PICC and Midline businesses divestment to Spectrum Vascular to optimize its product portfolio and to focus on strengthening its med tech segment.
Why AngioDynamics (ANGO) Outpaced the Stock Market Today
by Zacks Equity Research
AngioDynamics (ANGO) closed at $6.17 in the latest trading session, marking a +1.31% move from the prior day.
AngioDynamics (ANGO) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
The latest trading day saw AngioDynamics (ANGO) settling at $6.09, representing a -0.98% change from its previous close.